Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
BMC Cardiovasc Disord. 2024 Jul 29;24(1):391. doi: 10.1186/s12872-024-04067-8.
Rheumatic mitral stenosis (MS) remains a common and concerning health problem in Asia. Percutaneous balloon mitral valvuloplasty (PBMV) is the standard treatment for patients with symptomatic severe MS and favorable valve morphology. However, studies on the incidence and predictors of adverse cardiac outcomes following PBMV in Asia have been limited. This study aims to evaluate the incidence and predictors of adverse outcomes in patients with rheumatic MS following PBMV.
A retrospective cohort study was conducted on patients with symptomatic severe MS who underwent successful PBMV between 2002 and 2020 at a tertiary academic institute in Thailand. Patients were followed up to assess adverse outcomes, defined as a composite of cardiac death, heart failure hospitalization, repeat PBMV, or mitral valve surgery. Univariable and multivariable analyses were performed to identify predictors of adverse outcomes. A p-value of < 0.05 was considered statistically significant.
A total of 379 patients were included in the study (mean age 43 ± 11 years, 80% female). During a median follow-up of 5.9 years (IQR 1.7-11.7), 74 patients (19.5%) experienced adverse outcomes, with an annualized event rate of 2.7%. Multivariable analysis showed that age (hazard ratio [HR] 1.03, 95% confidence interval [CI] 1.008-1.05, p = 0.006), significant tricuspid regurgitation (HR 2.17, 95% CI 1.33-3.56, p = 0.002), immediate post-PBMV mitral valve area (HR 0.39, 95% CI 0.25-0.64, p = 0.01), and immediate post-PBMV mitral regurgitation (HR 1.91, 95% CI 1.18-3.07, p = 0.008) were independent predictors of adverse outcomes.
In patients with symptomatic severe rheumatic MS, the incidence of adverse outcomes following PBMV was 2.7% per year. Age, significant tricuspid regurgitation, immediate post-PBMV mitral valve area, and immediate post-PBMV mitral regurgitation were identified as independent predictors of these adverse outcomes.
风湿性二尖瓣狭窄(MS)仍然是亚洲常见且令人关注的健康问题。经皮球囊二尖瓣成形术(PBMV)是治疗有症状的严重 MS 和有利瓣膜形态患者的标准治疗方法。然而,亚洲关于 PBMV 后不良心脏结局发生率和预测因素的研究有限。本研究旨在评估经 PBMV 治疗的风湿性 MS 患者的不良结局发生率和预测因素。
对 2002 年至 2020 年期间在泰国一家三级学术机构接受成功 PBMV 的有症状严重 MS 患者进行回顾性队列研究。对患者进行随访以评估不良结局,定义为心脏死亡、心力衰竭住院、重复 PBMV 或二尖瓣手术的复合结局。进行单变量和多变量分析以确定不良结局的预测因素。p 值<0.05 被认为具有统计学意义。
本研究共纳入 379 例患者(平均年龄 43±11 岁,80%为女性)。在中位随访 5.9 年(IQR 1.7-11.7)期间,74 例患者(19.5%)发生不良结局,年发生率为 2.7%。多变量分析显示,年龄(风险比[HR] 1.03,95%置信区间[CI] 1.008-1.05,p=0.006)、显著三尖瓣反流(HR 2.17,95%CI 1.33-3.56,p=0.002)、PBMV 即刻后二尖瓣瓣口面积(HR 0.39,95%CI 0.25-0.64,p=0.01)和 PBMV 即刻后二尖瓣反流(HR 1.91,95%CI 1.18-3.07,p=0.008)是不良结局的独立预测因素。
在有症状的严重风湿性 MS 患者中,PBMV 后不良结局的发生率为每年 2.7%。年龄、显著三尖瓣反流、PBMV 即刻后二尖瓣瓣口面积和 PBMV 即刻后二尖瓣反流是这些不良结局的独立预测因素。